MIDOL COMPLETE OTC
Generic Name and Formulations:
Acetaminophen 500mg, caffeine 60mg, pyrilamine maleate 15mg; caplets.
Bayer Corp, Consumer Care Div.
Indications for MIDOL COMPLETE:
2 caplets every 6hrs; max 6/day.
<12yrs: consult physician.
Concomitant other acetaminophen-containing products.
Acetaminophen: hepatic disease. Pyrilamine: asthma, emphysema, other lower respiratory disorders. Glaucoma. GI or urinary obstruction. Discontinue if skin or allergic reactions occur. Reevaluate if pain worsens or lasts >10 days or fever persists or worsens >3 days. Pregnancy. Nursing mothers.
Analgesic + diuretic + sedating antihistamine.
Acetaminophen: increased risk of hepatotoxicity if overdosage or ≥3 alcoholic drinks/day. Pyrilamine: potentiates CNS depression with alcohol, other CNS depressants. Caution with warfarin, sedatives, or tranquilizers.
Acetaminophen: hepatotoxicity (overdosage). Pyrilamine: drowsiness, dizziness, paradoxical excitation (esp. in children). Caffeine: nervousness, irritability, sleeplessness, occasional palpitations.
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments